Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22834186 | 0.88 | CHRM5 (0.30) | CHRM5CHRM3 | |
| SCHEMBL9801292 | 0.88 | SIGMAR1 (0.34) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 | |
| SCHEMBL15471 | 0.82 | HRH3 (0.37) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 | |
| SCHEMBL20569862 | 0.82 | HRH3 (0.37) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 | |
| Hydrochloric Acid SCHEMBL64916 | 0.80 | SMN1; SMN2 (0.38) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 | |
| Methyl Alcohol SCHEMBL27940927 | 0.80 | HRH3 (0.36) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 | |
| SCHEMBL9813407 | 0.80 | HRH3 (0.36) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 | |
| SCHEMBL18855182 | 0.80 | CHRM5 (0.36) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 | |
| SCHEMBL17916212 | 0.80 | OPRL1 (0.40) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 | |
| SCHEMBL3822012 | 0.80 | SIGMAR1 (0.36) | CHRM5CHRM3SIGMAR1SMN1; SMN2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110101588-A | A kind of whitening and spot-eliminating composition and its shin moisturizer and preparation method | 广州市茗妍化妆品有限公司 | 2019-08-09 | — | — | CN | claimed |
| WO-2024111974-A1 | METHOD FOR MASS PRODUCTION OF IMMUNOSUPPRESSIVE T CELLS USING HUMAN SERUM ALBUMIN | 가톨릭대학교 산학협력단 | 2024-05-30 | — | — | WO | disclosed |
| WO-2022240240-A1 | COMPOSITION FOR NK CELL CRYOPRESERVATION, AND CRYOPRESERVATION FORMULATION COMPRISING SAME | 주식회사 지아이셀 | 2022-11-17 | — | — | WO | disclosed |
| CN-110448500-A | Yi Zhong treatment oil essence | GUANGDONG GADETIN DAILY NECESSITIES LTD | 2019-11-15 | — | — | CN | disclosed |
| US-20090221539-A1 | METHOD OF DETECTING AND REDUCING BOAR TAINT USING NUCLEAR RECEPTORS | UNIVERSITY OF GUELPH (CA) | 2009-09-03 | — | — | US | disclosed |
| EP-1969126-A1 | METHOD OF DETECTING AND REDUCING BOAR TAINT USING NUCLEAR RECEPTORS | University of Guelph (CA) | 2008-09-17 | — | — | EP | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007068115-A1 | METHOD OF DETECTING AND REDUCING BOAR TAINT USING NUCLEAR RECEPTORS | UNIVERSITY OF GUELPH (CA) | 2007-06-21 | — | — | WO | disclosed |
| EP-1552816-B1 | Cosmetic composition comprising an organosiloxane elastomer and a amino-sulfonic compound. | OREAL (FR) | 2006-11-08 | — | — | EP | disclosed |
| EP-1552816-A1 | Cosmetic composition comprising an organosiloxane elastomer and a amino-sulfonic compound. | L'OREAL (FR) | 2005-07-13 | — | — | EP | disclosed |
| EP-0739334-A1 | BIOMOLECULE SOLUBILISATION AGENTS CONSISTING OF NON-DETERGENT ZWITTERIONS, AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995019339-A1 | BIOMOLECULE SOLUBILISATION AGENTS CONSISTING OF NON-DETERGENT ZWITTERIONS, AND USES THEREOF | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1995-07-20 | — | — | WO | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | CHRM5 851/4885CHRM3 857/4885SIGMAR1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.